Karyopharm Therapeutics Inc Stock Ownership - Who owns Karyopharm Therapeutics?

Insider buying vs selling

Have Karyopharm Therapeutics Inc insiders been buying or selling?
Stuart PoultonEVP Chief Development Officer2024-02-1599$1.40
Stuart PoultonEVP Chief Development Officer2024-02-155,748$1.33
Michael MasonEVP CFO Treasurer2024-02-064,205$1.59
Richard A. PaulsonPresident and CEO2024-02-064,012$1.59
Richard A. PaulsonPresident and CEO2024-01-044,114$0.82
Richard A. PaulsonPresident and CEO2023-12-043,622$0.79
Richard A. PaulsonPresident and CEO2023-11-063,606$0.92
Richard A. PaulsonPresident and CEO2023-10-043,589$1.27
Garen G. BohlinDirector2023-09-1241,140$1.22
Richard A. PaulsonPresident and CEO2023-09-0564$1.32

1 of 4

KPTI insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when KPTI insiders and whales buy or sell their stock.

KPTI Shareholders

What type of owners hold Karyopharm Therapeutics Inc stock?
Chione Ltd14.19%16,258,079$20.16MInsider
Blackrock Inc8.79%10,071,677$12.49MInstitution
Vanguard Group Inc7.60%8,710,158$10.80MInstitution
Avidity Partners Management LP7.25%8,298,570$10.29MInstitution
Plio Ltd5.53%6,336,946$7.86MInsider
Marcin Czernik5.18%5,930,939$7.35MInsider
Palo Alto Investors LP4.45%5,102,193$6.33MInstitution
Citadel Advisors LLC2.71%3,101,399$3.85MInstitution
Geode Capital Management LLC2.08%2,382,428$2.95MInstitution
Gsa Capital Partners LLP2.04%2,337,985$2.90MInstitution

1 of 3

KPTI vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
KPTI64.13%31.90%Net SellingNet Selling
SGMT39.97%60.03%Net BuyingNet Buying
ORMP12.78%46.63%Net Buying

Karyopharm Therapeutics Stock Ownership FAQ

Who owns Karyopharm Therapeutics?

Karyopharm Therapeutics (NASDAQ: KPTI) is owned by 64.13% institutional shareholders, 31.90% Karyopharm Therapeutics insiders, and 3.97% retail investors. Chione Ltd is the largest individual Karyopharm Therapeutics shareholder, owning 16.26M shares representing 14.19% of the company. Chione Ltd's Karyopharm Therapeutics shares are currently valued at $20.16M.

If you're new to stock investing, here's how to buy Karyopharm Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.